OncoCyte Corp (STU:7OC0)
€ 3.34 0 (0%) Market Cap: 32.55 Mil Enterprise Value: 30.49 Mil PE Ratio: 0 PB Ratio: 1.89 GF Score: 32/100

OncoCyte Corp - EGFR And Molecular Risk Stratification In Early-Stage NSCLC Transcript

Oct 22, 2020 / 06:00PM GMT
Release Date Price: €27.4 (+1.48%)
Sara Riordan
OncoCyte Corporation - Director of Medical Education

Hello, and welcome to today's webinar. My name is Sara Riordan. I'm a Genetic Counselor and the Director of Medical Education at Oncocyte. We are very fortunate today to be joined by leading lung cancer experts to discuss brand-new data regarding molecular risk stratification in the context of EGFR testing in early-stage lung cancer. This webinar is being recorded, and we'll make the recording available after the webinar.

Now I'd like to introduce our speakers and panelists. Our first speaker is Dr. Gavitt Woodard, a thoracic surgeon and Assistant Professor at (Trades, Portfolio). She received her medical degree from Stanford University and completed her general surgery residency and cardiothoracic surgery fellowship at UCSF. Dr.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot